Literature DB >> 19616828

A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States.

Claudio Jeldres1, Sara Baillargeon-Gagne, Daniel Liberman, Hendrik Isbarn, Umberto Capitanio, Shahrokh F Shariat, Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Francesco Montorsi, Markus Graefen, Pierre I Karakiewicz.   

Abstract

OBJECTIVE: To examine temporal, geographic, socioeconomic, and clinical determinants of cytoreductive nephrectomy (CNT) use in the surveillance, epidemiology, and end results (SEER) database, because CNT is known to improve survival in patients with metastatic renal cell carcinoma (mRCC).
METHODS: Within the SEER database, we identified 6226 mRCC patients, who were either treated with CNT (n = 2038) or underwent no surgery (n = 4188) between 1989 and 2004. Chi-square and chi(2) trend tests, as well as multivariate logistic regression models, were used to assess the effect of age, gender, race, region of residence, and year of surgery on the rate of CNT. Adjustment was made for the size of the primary tumor.
RESULTS: The overall rate of CNT was 30.5%. The rate of CNT increased in the most recent year quartile (P <.001), was more frequent in white patients (P = .005), males (P = .001), and younger patients (P <.001). Moreover, CNT was more frequently performed for larger primary tumors (P <.001). Finally, important variability was found to exist in the rate of CNT between the 9 SEER registries (range 29.5%-38.6%, P = .002). In multivariate logistic regression models, age (P <.001), race (P <.001), year of surgery (P <.001), primary tumor size (P <.001), and SEER region (P = .003) were independent predictors of CNT rate.
CONCLUSIONS: Racial and geographic variability in CNT rates is worrisome and warrants further attention. In view of the survival benefits of CNT, its access should be equal for all races and regions.

Entities:  

Mesh:

Year:  2009        PMID: 19616828     DOI: 10.1016/j.urology.2009.04.019

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

Review 1.  Treatment of metastatic renal cell carcinoma.

Authors:  Maxine Sun; Giovanni Lughezzani; Paul Perrotte; Pierre I Karakiewicz
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

Review 2.  Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Authors:  Paul L Crispen; Michael L Blute
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

3.  Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.

Authors:  Brian J Minnillo; William Tabayoyong; John J Francis; Matthew J Maurice; Hui Zhu; Simon Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

4.  Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).

Authors:  Ayal A Aizer; Yuksel Urun; Rana R McKay; Adam S Kibel; Paul L Nguyen; Toni K Choueiri
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

5.  Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives.

Authors:  Makarand V Khochikar
Journal:  Indian J Surg Oncol       Date:  2016-12-08

6.  Trends in the use of cytoreductive nephrectomy in the United States.

Authors:  Che-Kai Tsao; Alexander C Small; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2012-05-30       Impact factor: 2.872

7.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

8.  Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

Authors:  Simon L Conti; I-Chun Thomas; Judith C Hagedorn; Benjamin I Chung; Glenn M Chertow; Todd H Wagner; James D Brooks; Sandy Srinivas; John T Leppert
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

9.  Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.

Authors:  Wen-Jun Xiao; Yao Zhu; Bo Dai; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

10.  Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.

Authors:  Wataru Obara; Takashi Karashima; Kazuyoshi Takeda; Renpei Kato; Yoichiro Kato; Mitsugu Kanehira; Ryo Takata; Keiji Inoue; Toyomasa Katagiri; Taro Shuin; Yusuke Nakamura; Tomoaki Fujioka
Journal:  Cancer Immunol Immunother       Date:  2016-10-18       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.